Physician profile
Robert R Seidel
NPI 1760488209
$664.91
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $649 · 2020: $15.63.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $129.50 | 2019 | |
| Astellas Pharma US INC | $119.58 | 2019 | |
| Sunovion Pharmaceuticals INC. | $116.43 | 2019 | |
| Amgen INC. | $78.18 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $44.70 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.04 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $20.33 | 2019 | |
| Cardiovascular Systems INC. | $18.79 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.80 | 2019 | |
| Alexion Pharmaceuticals, INC. | $14.11 | 2019 | |
| Grifols USA, LLC | $13.62 | 2019 | |
| Gilead Sciences, INC. | $12.68 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.46 | 2019 | |
| Glaxosmithkline, LLC. | $11.70 | 2019 | |
| Daiichi Sankyo INC. | $11.52 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $11.47 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Seidel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.